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Heterocyclic rings are a recurring and iconic motif in organic
chemistry. The introduction of five-membered rings into
protein backbones is synthetically challenging, but many
peptide-based biologically active natural products contain
such Ser-, Thr-, and Cys-derived heterocycles[1] and therefore
a facile route to their introduction is highly desirable. More
generally thiazolines and oxazolines, as well as their oxidized
forms (thiazoles and oxazoles), are found in a variety of
approved drugs, drug leads, and toxins.[2]
The cyanobacterium Prochloron spp. produces multiple
macrocyclic cyanobactins, which are known as the trunka-
mides (seven or eight residues) and the patellamides (eight
residues). These natural products originate from two different
ribosomal precursor peptides (denoted TruE and PatE), and
each ribosomal peptide contains multiple distinct core
peptides. In TruE (and PatE), each of the core peptides is
flanked at the N-terminus by a conserved five-residue
protease signature[3] and at the C-terminus by a conserved
macrocyclization signature (A/SYDG; Scheme 1). It is the
core peptides that go on to become the different natural
products. In trunkamides and patellamides (as well as other
cyanobactins) these products possess multiple heterocyclic
cysteine, and/or serine and threonine amino acids. All
cyanobactin ribosomal precursor peptides possess (along
with the core peptides and their flanking regions) a conserved
thirty- to forty-residue N-terminus (Scheme 1). This N-
terminal leader, which is discarded during processing is
thought to be essential for heterocyclization.[4] Heterocycli-
zation of the multiple cysteine residues in TruE is carried out
by the single enzyme, TruD, which by definition is processive.
The amino acid sequence of the core peptide is variable
(Supporting Information, Figure S1) and thus TruD must be
in part insensitive to the immediate sequence context of the
target cysteine (Scheme 1). Further, the positions of the target
cysteines in TruE relative to the leader vary, both within and
between core peptides. This flexibility suggests that TruD
could be valuable for synthetic chemists. The corresponding
enzyme in the patellamide pathway is denoted PatD. TruD
and PatD process cysteine residues[4,5] in the other enzymes
precursor peptide substrate equally well; TruD processes
serine and threonine residues less well than PatD.[4,5] The
interchangeability of enzymes mirrors the high degree of
sequence identity in the enzymes (Figure S2) and substrate N-
terminal leader (Figure S1).
The heterocyclization of cysteine to form thiazoline as
part of the microcins (thiazole/oxazole-modified microcins, or
TOMMs) has recently been studied and the responsible ATP
Mg2+ dependent heterocyclase BalhD identified.[6] BalhD is
homologous to the C-terminal 400 residues of TruD, whilst
a second protein BalhC matches the N-terminal 300 residues
(Figure S2). When both BalhD and BalhC are present
heterocyclization of the microcin substrate is accelerated
and only when both proteins are present can phosphate
release be robustly measured. Pyrophosphate production by
BalhD was ruled out and BalhD was proposed to operate by
Scheme 1. Heterocyclization reaction catalyzed in the cyanobactins.
TruD efficiently processes cysteines and selenocysteine.[8] TruD oper-
ates on core peptides of seven or eight residues; a single precursor
peptide can contain up to four core peptides each with different
sequences. The immediate sequence context and position (relative to
the leader) of the target cysteine is variable.
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a kinase type mechanism in which a hemiorthoamide inter-
mediate is phosphorylated[6,7] (Figure S3).
The cyanobactin class of heterocyclases, exemplified by
TruD, possess an almost unique combination of processivity,
specificity, chemical versatility, and promiscuity, which thus
makes them a fascinating subject for study. We show by
biochemical assay that TruD is an adenylase, not a kinase, and
that TruD processes cysteines in a defined order, which we
describe. We demonstrate that entire substrate leader can be
removed and TruD will process a single specific cysteine
residue. However, we establish the role of leader is to permit
processivity through a balance of recognition.
TruD overexpressed in E. coli BL21 (DE3) cells and
purified to homogeneity (as judged by SDS-PAGE) using
established procedures[8] was used for all analyses. TruD
(5 mm), when incubated with Mg2+, ATP (5 mm) and an
engineered PatE2 (single core peptide sequence ITACITFC,
Figure S1; 100 mm) results in a loss of mass in PatE2 of two
water molecules (Figure S4a). Mass spectrometry (MS)
fragmentation data confirms the formation of heterocycles,[5,8]
validating TruD activity and substrate. 2.2 molar excess of
ATP (1.1 for cysteines) was added to PatE2 at 20 8C and
incubated with TruD for 8 h and immediately the product of
the reaction was analyzed by 1D 31P NMR spectroscopy.
Authentic AMP, ADP, ATP, pyrophosphate, and phosphate in
the same buffer at the same concentration and pH were used
as standards (Figure 1a,b). Two new peaks matching AMP
and pyrophosphate were identified in the product mixture.
Unreacted ATP and a smaller amount of phosphate were
observed, but no ADP. We repeated the experiment at 10 8C
and recorded spectra every 30 min for the first 12 h and every
2 h thereafter (Figure S5a). This time-course confirms AMP
and pyrophosphate production (and small amount of phos-
phate). A control incubation of the mixture with ADP reveals
that it only slowly degrades to AMP. These data can only be
explained by an adenylation mechanism and rules out
a kinase mechanism. Repeating the NMR after overnight
incubation or at a temperature > 25 8C shows only phosphate
(Figure S5b), a fact we attribute to pyrophosphate degrada-
tion rather than a time- or temperature-dependent change in
mechanism.
ATP, ADP, and AMP bind to TruD with KD values of 19,
20, and 12 mm, respectively (Figure S5c), but as ADP decom-
poses slowly in a dissipated exothermic manner, the corre-
spondingKD value is an apparent value obtained by analyzing
the rapidly emerging endothermic parts of the ITC signals.
Although dTTP does not bind in ITC experiments, we find it
and GTP can catalyze heterocyclization of cysteine (Fig-
ure S5d–f); BalhD has also been shown to use GTP.[9]
The coupled NADH assay reported in the study of the
adenylase enzyme AcsD[10] uses lactate dehydrogenase to
oxidize NADH during the reduction of pyruvate. Pyruvate is
generated by pyruvate kinase, which requires ADP. The assay
has a background rate in the absence of any substrate,[10]
which for a slow enzyme such as TruD is significant. The
addition of TruD and/or PatE2 to the mixture did not increase
the rate of NADH consumption above background, indicat-
ing no enzymatic production of ADP. Addition of myokinase,
which converts AMP and ATP into ADP, accelerates the rate
of NADH consumption to 5.04 mmmin1 (Figure 1c), con-
firming enzymatic production of AMP consistent with an
adenylase mechanism.
Time-course MS experiments showed that although both
cysteines were heterocyclized after about 60 min at 37 8C,
there appeared to be an accumulation of a mono-hetero-
cyclized intermediate during the reaction (Figure S4b). Using
standard triple-resonance experiments, we assigned the
spectra (except four of the six histidine residues of the C-
terminal tag) of uniformly 13C, 15N-labeled PatE2 (Figure S6).
The sharp, poorly dispersed NMR signals and 13C chemical
shifts indicate PatE adopts a natively unfolded state in
aqueous buffer (compare with the helical arrangement of N-
terminal leader peptide in organic solvent[11]). Real-time 1H-
15N HSQC-NMR reaction monitoring using uniformly 15N-
labeled PatE2 showed a specific order with the first hetero-
cyclization event characterized by the disappearance of eight
cross-peaks (assigned to residues 48–55) and the emergence
of seven new cross-peaks (Figure 2). In the second hetero-
cyclization event, eight cross-peaks (residues 43–50) disap-
peared (three of which appeared with first heterocyclization)
and seven new peaks appeared (Figure 2).
Heterocyclization of cysteine induces large changes in
1HN, 15NH, Ca, and Cb chemical shifts (Figure S6). This allowed
us to establish that the terminal cysteine, C51, heterocyclizes
Figure 1. PatE2 TruD reaction. a) 31P NMR of a heterocyclization reac-
tion, authentic AMP, pyrophosphate (PPi), ADP, phosphate (P), and
ATP. AMP and PPi predominate at end of reaction with small amounts
of phosphate and unreacted ATP present; no ADP is observed.
b) Expansion of the PPi peak in the final reaction and PPi standard.
c) Decrease of absorbance in the coupled NADH assay in the presence
(blue) and absence (black) of myokinase (MK). Reaction rates were
calculated from fitted curves (red and magenta, respectively). Addition
of MK accelerates the apparent rate by a factor of about 8.
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first, followed by the slower heterocyclization of the internal
cysteine C47 (Figure 2; Supporting Information, Figure S6).
The reaction was highly temperature-dependent with com-
pletion in under 5 h at 20 8C, but still incomplete after 44 h at
10 8C (Figure 2). The internal cysteine of the PatE2 mutant
C51P (chosen to mimic the mono-heterocyclized intermedi-
ate) was processed (within error) at the same rate as the
internal cysteine in PatE2 (Figure S7). However, the internal
cysteine of the C51A PatE2 mutant is processed very slowly
(Figure S7). The conformational change at the C-terminus of
core peptide introduced upon formation of the five-mem-
bered ring is thus critical for TruD to be able to process the
internal cysteine of the core peptide.
We incubated a uniformly 15N-labeled PatE with a core
peptide with three cysteines (sequence ICACITFC (PatE3C))
and monitored the reaction by HSQC NMR at 10 8C and
observed that C51 reacts first, followed by C47 and finally
C45 (Figure S8). TruD thus works from the C-terminus within
the core, but the accumulation of the intermediates shows that
they are released and rebound, rather than held on the
enzyme. The first two heterocyclizations of PatE3 occur on an
identical timescale (at both 10 8C and 37 8C) to the two-
cysteine PatE2 substrate, but the third heterocyclization is
slower than the second heterocyclization (which is slower
than the first).
PatE2 binds very tightly to TruD (KD 80 nm) (Figure 3),
but titrating TruD into 15N-PatE2 shows that 1H, 15N-HSQC
cross-peaks of residues 1–15 are unaffected and thus do not
bind to TruD (Figure S6e); they might therefore have no role
in substrate recognition.
Using MS fragmentation analysis and ITC (where the
substrate was sufficiently soluble), we sought to define the
role of precursor peptide residues outside the core peptide in
controlling substrate recognition. A synthetic peptide with
the first 25 residues of PatE2 deleted (D25PatE) retains the
most conserved leader region, residues 26-35 (denoted
“minimal leader”), and was processed by TruD only slightly
more slowly than PatE2 (judged by MS; Figure S9). Insertion
of up to six amino acids between the N-terminal protease
signature, and the core peptide permitted normal heterocyc-
lization (Figure S7, Table S1). Four further synthetic peptides
were tested: D37PatE (retains five-residue protease signa-
ture) D42PatE (no leader), the eight-residue core peptide
itself and the eight-residue core peptide with an additional C-
terminal Gly (Figure S9). No reaction is seen with core
peptide alone or core peptide with C-terminal Gly. The
terminal cysteine only is however processed in both D37PatE
and D42PatE peptides (more slowly than D25PatE but within
an order of magnitude). From these data we conclude that
recognition of the C-terminal cysteine of the cassette does not
require the leader.
Radical mutants of individual residues within the center of
the minimal leader region revealed S30F had no effect but
mutants L29R and E31R did not allow processing of the
PatE2 to completion. In both cases, we observed the mono-
heterocyclized intermediate along with the product but no
unreacted substrate, indicating that the rate of the second
heterocyclization is significantly slower in these mutants but
the rate of the first heterocyclization is largely unaffected.
Both mutations significantly decreased binding affinity (Fig-
ure S7). Mutations G38I, L39N, A41I, and S42C within
GLEAS protease signature had little or no effect on
processing (first and second heterocyclization; E40R was
insoluble in our hands); although the binding was decreased
(Figure S7). The “new” cysteine of S42C was not processed by
TruD. Y53A and D54R (in the C-terminal macrocyclization
signature) were processed normally. Processivity (heterocyc-
lization of the second or internal cysteine of the core peptide),
although very sensitive to changes in the minimal leader, is
insensitive to changes in the core peptide flanking regions. We
explored more radical mutants S42Q and A52D, which
immediately flank the core peptide; both mutants signifi-
cantly disrupted binding and processing. In contrast to
changes in the leader peptide however, these mutations
primarily produced either fully heterocyclized product or
unreacted substrate. This suggests that these mutations affect
the rate of the first heterocyclization (C-terminal cysteine),
which has now become rate-limiting, but the mutations do not
significantly perturb heterocyclization of the internal cysteine
Figure 2. PatE2-TruD reaction monitoring and binding analysis. Over-
lay of HSQC spectra of 15N-PatE2 in presence of ATP/Mg2+ without
TruD (black cross-peaks) and 8 h (left panel, blue cross-peaks) or 44 h
(right panel, red cross-peaks) after addition of the enzyme. Resonan-
ces that disappear in the course of the transformation are labeled
black; emerging resonances are labeled blue (8 h) and red (44 h). The
cross-peak for C-terminal His64 undergoes a gradual chemical shift
change in the course of the reaction (fast chemical exchange rather
than the slow exchange observed for other affected resonances).
Figure 3. ITC data obtained for the injection of PatE and PatE variants
into TruD solutions. The top panels show raw data representing the
response to injections, the bottom panels show integrated heats of
injections (&) and the best fit (c) to the one-site model (origin).
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(the processivity). The PatE2A52P mutant has the internal
cysteine processed first and only very slowly has the terminal
cysteine processed. ITC shows that PatE2 C51A binds almost
as tightly as PatE2, but as the internal cysteine is processed
extremely slowly, we conclude this binding is non-productive;
the Ala at position 51 is bound at the active site. The PatE2
C51P mutant, which mimics the mono-heterocyclized inter-
mediate and permits normal processing of the internal
cysteine, binds much more weakly (1500 nm). We suggest
this weaker binding allows the internal cysteine to access the
active site.
The structure of TruD was determined to 2.9  (PDB
4BS9) and can be decomposed into three domains (domain 1
residues 2–85, domain 2 residues 86–321, domain 3 residues
323–781), which combine to form an extended, curved
molecule that exists as a dimer (Figure 4a).
Domains 1 and 2 of TruD share 21% sequence identity
and structural fold with the enzyme MccB, an adenylase
found in the microcin C7 antibiotic production pathway
(MccB catalyzes two successive adenylation reactions; Fig-
ure S10).[12] Pairwise superposition of TruD with the MccB
structure gives a Ca rmsd of 5.4  over 219 structurally
equivalent residues (MccB lacks the third domain; Figure 4b;
Supporting Information, Figure S11); individual domain
superpositions are much lower due to a domain rotation
(2.6  over 80 residues and 2.0  over 152 residues). TruD
and MccB possess a similar dimeric arrangement (Figure 4a)
and both share two CXXC motifs in domain 2 that bind
a Zn2+ ligated in a tetrahedral arrangement of sulfur atoms.
Both motifs are conserved in cyanobactin heterocyclases and
these motifs (and associated zinc) are a conserved feature of
one class of adenylating enzymes. The coordinatively satu-
rated zinc plays a structural role only[12b,13] in this class of
adenylating enzymes.
Domain 2 of TruD shares the fold of this class of
adenylating enzymes; other members include human ubiq-
uitin-activating enzyme 5 (1.9  rmsd over 134 Cas) and
thiamine pyrophosphate biosynthetic enzyme ThiF (2.1 
over 142 Cas). There is, however, a subtle topology differ-
ence; all the adenylating enzymes that share a fold with TruD
have an insertion between the first and second strand of the
central b-sheet relative to TruD domain 2. Significantly this
means that the ATP binding site of MccB is not fully
conserved in TruD (Figure S11). The ATP-bound structure of
MccB (PDB 3H5N) would suggest R123, K190, R221, and
R253 of TruD as possible ATP binding residues. R123A
retained native activity and the three other TruD mutants
were insoluble. D165 in TruD is conserved both in hetero-
cyclases and in the adenylase superfamily but the TruD
mutant D165A retained native activity. Structural data of
course do not establish the mechanism but they are entirely
consistent with TruD being an adenylase enzyme. The 20%
sequence identity of BalhC to TruD (including the two CXXC
motifs; Figure S2), establishes that BalhC will have the same
fold as domains 1 and 2 of TruD and thus its fold will belong to
the same class of adenylating enzymes.
Domain 3 of TruD is a novel fold and has a large
negatively charged central cleft (Figure S11). In our hands
the third domain of TruD or PatD, expressed separately, is
insoluble, but by proteolysis of PatD (highly homologous to
TruD) we were able to purify part of the third domain
(residues 410–784). In contrast to full-length PatD, which is
active, the fragment possessed no catalytic or substrate
binding activity (Figure S12). BalhD[6] with 23% identity
will have the same fold as TruD domain 3 and thus possesses
an entirely new fold for kinase chemistry.
Biochemical analysis of TruD conclusively rules out
a kinase mechanism for this enzyme as there is no ADP
production. As both AMP and pyrophosphate are directly
detected during turnover, the data can only be interpreted as
an adenylation-type mechanism. We did observe phosphate
(rather than pyrophosphate) at higher temperature or after
prolonged incubation, but this is consistent with degradation
of the reactive pyrophosphate. Chemical reasoning would
suggest the carbonyl oxygen of amides is too unreactive
a nucleophile to react directly with ATP. In any event, such
a mechanism would seem to invite futile ATP consumption
(adenylation of carbonyl followed by hydrolysis), which is not
observed. The most plausible mechanism therefore requires
the formation of a five-membered hemiorthoamide ring in
a reversible step (Scheme 2), proposed by Dunbar et al.[6] in
the BalhD mechanism. The general base required for the first
Scheme 2. Proposed mechanism for heterocyclization by the TruD
class of enzyme. Abstraction of the sulfhydryl proton leads to the
formation of a hemiorthoamide, which is adenylated. Irreversible
elimination of AMP leads to the formation of the thiazoline. PPi=pyr-
ophosphate.
Figure 4. Structure of TruD. a) Structure of the biological TruD dimer.
Domain 1 (blue), domain 2 (yellow), domain 3 (red), and the cova-
lently bound Zn (gray sphere in domain 2, near domain 3) are shown.
The dimer partner is represented in corresponding faded colors.
b) Structural alignment of TruD (domain 1 blue, domain 2 yellow) with
MccB (magenta, PDB 3H5A). The MccB ATP binding site is boxed.
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step could come from PatE but the observations that the
entire leader region can be removed, and the conserved
flanking residues extensively mutated argues against this. We
suggest the hemiorthoamide intermediate attacks the a-
phosphate of ATP displacing pyrophosphate giving an
adenylated hemiorthoamide. This highly reactive intermedi-
ate decomposes to thiazoline and by rapid irreversible
elimination of AMP (Scheme 2).
The difference in mechanism of phosphorylation versus
adenylation between BalhD and TruD is unexpected; espe-
cially given their sequence and by extension structural
homology and their shared chemical reaction. We speculate
that BalhD and the third domain of TruD both catalyze the
reversible formation of the hemiorthoamide ring. In TruD,
domain 2 then adenylates the intermediate whilst in the
TOMM pathway, BalhC docks to BalhD and somehow
accelerates the phosphorylation. These data suggest that
heterocyclases join a very small number of enzymes exem-
plified by the type I and type II aldolases, which catalyze the
same reaction, share a fold yet operate by entirely different
chemical mechanisms.
TruD and its homologues have to process multiple (> 8)
cysteines scattered throughout a larger precursor peptide.
NMR showed TruD operates in strict order with the terminal
cysteine in the core peptide reacting first; the next most C-
terminal cysteine then reacts, and so on (Scheme 3), thus
avoiding a combinatorial array of intermediates. The starting
material binds tightly (80 nm) whilst the mono-heterocyclized
intermediate (mimicked by PatE2 C51P) binds more weakly
(KD 1500 nm). Thus the intermediate only binds once all the
initial substrate is processed. The requirement for a five-
membered ring at the end of the core peptide for processing
mirrors the situation for the macrocyclase PatG,[14] but for the
opposite reason. In the macrocyclase the ring is essential for
binding of the substrate, but for the heterocyclase it is
essential to prevent unproductive substrate binding at an
already processed residue: a form of chemical check point
(Scheme 3).
The entire leader peptide could be dispensed with and the
terminal cysteine still processed (something similar has been
reported in the TOMM pathway[7]). This suggests somewhat
special recognition for the terminal cysteine focused on its
immediate environment, consistent with our mutational
analysis (Scheme 3). What is the role of the leader sequence?
We have shown that the leader sequence (crucially residues
26–37) is required for processivity (heterocyclization of
subsequent cysteines). We advance a model in which sub-
strate recognition involves both the target residue and the
leader, the contribution of each of these to overall substrate
binding shifts during processing and it is this differential
binding that controls the order of heterocyclization.
As multiple core peptides share a single leader, the
signatures flanking the core peptide can be mutated exten-
sively and insertion of residues between the core and leader
can be tolerated; we conclude that the spatial relationship
between the minimal leader and target residue is highly
flexible. This separation of recognition and catalysis is rare
and should help drive the use of the enzyme in chemical
synthesis.
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The Cyanobactin Heterocyclase Enzyme:
A Processive Adenylase That Operates
with a Defined Order of Reaction
Counting backwards : The cyanobactin
class of heterocyclases, exemplified by
TruD, possess an almost unique combi-
nation of processivity, specificity, chem-
ical versatility, and promiscuity. TruD is
shown by biochemical assay to be an
adenylase, and processes cysteines in
a defined order. The entire substrate
leader can be removed and TruD will
process a single specific cysteine residue;
however the role of leader is to permit
processivity through a balance of recog-
nition. ATP/AMP=adenosine tri/mono-
phosphate; PPi=pyrophosphate.
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